Esperion Therapeutics vs Amarin Which Is Stronger?

Esperion Therapeutics and Amarin are two prominent players in the pharmaceutical industry, each specializing in cardiovascular drugs. Esperion focuses on developing innovative therapies for the treatment of high cholesterol, while Amarin is known for its cardiovascular drug Vascepa, which is used to lower triglyceride levels. Both companies have experienced fluctuations in their stock prices, with investors closely monitoring their success in bringing new drugs to market and gaining regulatory approval. Understanding the dynamics of the pharmaceutical market is essential for investors looking to capitalize on opportunities in this sector.

Esperion Therapeutics or Amarin?

When comparing Esperion Therapeutics and Amarin, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Esperion Therapeutics and Amarin.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Esperion Therapeutics has a dividend yield of -%, while Amarin has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Esperion Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Amarin reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Esperion Therapeutics P/E ratio at -5.05 and Amarin's P/E ratio at -4.75. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Esperion Therapeutics P/B ratio is -1.18 while Amarin's P/B ratio is 0.35.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Esperion Therapeutics has seen a 5-year revenue growth of -0.84%, while Amarin's is -0.02%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Esperion Therapeutics's ROE at 23.71% and Amarin's ROE at -7.22%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $1.84 for Esperion Therapeutics and $0.45 for Amarin. Over the past year, Esperion Therapeutics's prices ranged from $1.58 to $3.94, with a yearly change of 149.37%. Amarin's prices fluctuated between $0.45 and $1.37, with a yearly change of 207.04%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.